Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 76
- Registration Number
- NCT01923558
- Locations
- 🇨🇦
Algorithme Pharma Inc., Mount Royal, Quebec, Canada
Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01903824
- Locations
- 🇳🇱
Teva Investigational Site 38051, Leiden, Netherlands
A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 5
- Registration Number
- NCT01887132
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 188
- Registration Number
- NCT01849042
- Locations
- 🇰🇷
Konkuk university medical center, Seoul, Korea, Republic of
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 41
- Registration Number
- NCT01845636
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Registration Number
- NCT01822951
- Locations
- 🇦🇹
AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Austria
Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 5
- Registration Number
- NCT01743976
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT01677754
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇨🇦Vancouver Island Health Authority, Victoria, British Columbia, Canada
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
Combination Treatment Study for Memory Impairment and Depression
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 86
- Registration Number
- NCT01658228
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 19
- Registration Number
- NCT01633593
- Locations
- 🇧🇷
FAMEMA, Marilia, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.